ArticleCurrent microbiology2026
Restoring Firmicutes-Associated Metabolites: A Gut-Brain Axis Approach to Alleviate Neuroinflammation and Oxidative Stress in Intracerebral Hemorrhage.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Intracerebral hemorrhage (ICH), a lethal stroke subtype, lacks therapies targeting gut-brain axis dysregulation. While gut microbiota influences ischemic stroke outcomes, how ICH perturbs microbial-metabolite interactions via the microbiota-gut-brain axis (MGBA) remains unknown. We combined a collagenase-induced ICH mouse model with multi-omics (16S rRNA sequencing, metabolomics) and functional assays (BV2 microglia) to investigate gut dysbiosis and metabolite alterations. Intestinal barrier integrity, neuroinflammation, and oxidative stress were assessed. At the phylum level, the control (CON) group exhibited a microbiome dominated by Firmicutes, Actinobacteriota, and Campylobacterota. In stark contrast, the ICH group displayed a pathological shift toward Bacteroidota, Cyanobacteria, and Proteobacteria. These dysbiotic alterations corresponded to intestinal barrier compromise marked by reduced expression of zonula occludens-1 (ZO-1), occludin, and mucin 2 (MUC2), systemic elevation of pro-inflammatory cytokines including interleukin-1β (Il-1β) and tumor necrosis factor-α (Tnf-α), and depletion of neuroprotective metabolites–specifically oleoyl ethanolamide, linoleoyl ethanolamide, and L-valine–whose levels positively correlated with Firmicutes abundance. Mechanistically, in vitro experiments demonstrated that these metabolites collectively suppressed neuroinflammation and neuronal apoptosis, with l-valine exhibiting unique antioxidant activity through Reactive oxygen species scavenging. Molecular docking studies have shown that linoleoyl ethanolamide (LEA) and oleoylethanolamide (OEA) can inhibit the levels of inflammatory cytokines interleukin-6 (Il-6) and tumor necrosis Tnf-α by binding to key sites. Our findings underscore the critical role of gut microbiota-metabolite crosstalk in ICH pathogenesis and identify microbial metabolites as potential therapeutic targets for preserving gut-brain axis homeostasis.
Indexed as
Identifiers
41774153What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.